<DOC>
	<DOCNO>NCT01980524</DOCNO>
	<brief_summary>There evidence inhibition FFA-release acipimox associate significant decrease myocardial lipid content ( MYCL ) well ejection fraction ( marker systolic leave ventricular function ) healthy subject , indicate , heart dependent constant supply free fatty acid order guarantee normal cardiac function , indicate , heart able cover energy demand switch glucose oxidation . Since phenomenon , good know `` metabolic inflexibility '' mainly describe patient diabetes , aim investigate impact FFA-inhibition MYCL cardiac function patient overt type 2 diabetes .</brief_summary>
	<brief_title>The Impact Free Fatty Acid ( FFA- ) Suppression Myocardial Lipids Function Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Type 2 Diabetes HbA1C &gt; 6 % Insulin therapy ( except : BOT=basal support oral therapy ) Known heart disease include coronary artery disease , cardiomyopathy , history cardiac surgery Known intolerance niacin Known contraindication magnetic resonance ( MR ) examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>